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The gut microbiome influences nutrient processing as well as host physiology. Plasma
lipid levels have been associated with the microbiome, although the underlying
mechanisms are largely unknown, and the effects of dietary lipids on the gut microbiome
in humans are not well-studied. We used a compilation of four studies utilizing
non-human primates (Chlorocebus aethiops and Macaca fascicularis) with treatments
that manipulated plasma lipid levels using dietary and pharmacological techniques, and
characterized the microbiome using 16S rDNA. High-fat diets significantly reduced alpha
diversity (Shannon) and the Firmicutes/Bacteroidetes ratio compared to chow diets, even
when the diets had different compositions and were applied in different orders. When
analyzed for differential abundance using DESeq2,Bulleidia,Clostridium,Ruminococcus,
Eubacterium, Coprocacillus, Lachnospira, Blautia, Coprococcus, and Oscillospira
were greater in both chow diets while Succinivibrio, Collinsella, Streptococcus, and
Lactococcus were greater in both high-fat diets (oleic blend or lard fat source).
Dietary cholesterol levels did not affect the microbiome and neither did alterations of
plasma lipid levels through treatments of miR-33 antisense oligonucleotide (anti-miR-33),
Niemann–Pick C1-Like 1 (NPC1L1) antisense oligonucleotide (ASO), and inducible
degrader of LDLR (IDOL) ASO. However, a liver X receptor (LXR) agonist shifted the
microbiome and decreased bile acid levels. Fifteen genera increased with the LXR
agonist, while seven genera decreased. Pseudomonas increased on the LXR agonist
and was negatively correlated to deoxycholic acid, cholic acid, and total bile acids while
Ruminococcus was positively correlated with taurolithocholic acid and taurodeoxycholic
acid. Seven of the nine bile acids identified in the feces significantly decreased due to the
LXR agonist, and total bile acids (nmol/g) was reduced by 62%. These results indicate
that plasma lipid levels have, at most, a modest effect on the microbiome, whereas bile
acids, derived in part from plasma lipids, are likely responsible for the indirect relationship
between lipid levels and the microbiome.
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INTRODUCTION
The microbiome plays an integral role in host dynamics of
health and disease, and this relationship is tied to diet. Decreased
health status has been associated with microbiome dysbiosis
(1–4), high-fat diets (5, 6), and increased plasma lipid levels
(7). Cholesterol and its lipoprotein carriers are important
contributors to cardiovascular disease, and recent evidence
suggests that the microbiome may play a role in this relationship
by influencing lipid metabolism (8–11).
Lipid levels in the blood are used as an indicator of
health, with about 40% of lipid variation attributed to genetics
(12). The rest is explained by the environment, which would
include diet and, more recently, the microbiome. Lipids have
been correlated to microbial taxa in mice (8), pigs (13), and
humans (14, 15), but the identified taxa have varied across the
studies. One recurring result is that increased alpha diversity
is correlated to elevated high-density lipoprotein (HDL) and
reduced triglyceride levels, but low-density lipoprotein (LDL)
appears to have little or no association with the microbiome (14–
16). Plasma cholesterol was influenced by manipulations of the
microbiome through antibiotic reduction and fecal transplants
and demonstrated a causal relationship between the microbiome
biome and circulating cholesterol (17).
Dietary lipids have a strong influence on host lipid levels
as well as the microbiome. High-fat diets are considered
unfavorable to health because they are related to increased LDL
levels (18) and cardiovascular disease, as well as “starving” the
microbiome by reducing microbially accessible carbohydrates
and fermentable fibers (19, 20). It is important to note
that fat composition (monounsaturated vs. polyunsaturated vs.
saturated) (21, 22), source (lard vs. fish oil) (23), and quality
(oxidized vs. unoxidized) are all characteristics that influence the
effect of fat.
Lipid metabolism and cholesterol levels are influenced by bile
acids, which are cholesterol derivatives synthesized in the liver
and secreted in bile via the gall bladder into the small intestine
(24). In the intestine, bile acids modulate bacterial composition
by restricting bacterial proliferation and growth (25). In turn,
bacterial enzymes modify bile acids through deconjugation,
epimerization, and dehydroxylation to produce secondary bile
acids (26). Ninety-five percent of bile acids in the intestine are
then reabsorbed into the enterohepatic circulation for further
modification, whereas 5% are excreted in feces. Germ-free rats
have been shown to have a reduction in circulating bile acids
(27), especially a reduction in secondary bile acids, compared
to conventionally raised rats. Furthermore, the role of bile acids
in signaling through the farnesoid-X-receptor (FXR) and the G-
protein coupled receptor, TGR5, may represent an additional
mechanism through which the microbiome interacts with the
mammalian host (28, 29).
It has proven difficult to determine the causal interactions
between the gut microbiome and plasma lipids directly
in humans. We have therefore attempted to address this
issue using studies of non-human primates. Here we use a
compilation of four non-human primate (NHP) studies with
dietary and pharmacological treatments that perturbed host
lipid levels. We found that high-fat diets with different fat
compositions and opposite ordering of diet treatments had
similar effects on the microbiome, but that the microbiome
did not significantly respond to changes in dietary cholesterol
and two pharmacological treatments that perturbed plasma
lipid metabolism. A pharmacological treatment that did affect
the microbiome was a liver X receptor (LXR) agonist, which
decreased levels of bile acids. These results indicate that plasma
lipid levels do not, or minimally, affect the microbiome but that
bile acids may be responsible for creating an indirect relationship
between the microbiome and plasma lipid levels.
MATERIALS AND METHODS
High-Fat Diet Oleic Blend Study Design
The design of this study was previously described (30) as follows:
Adult male African green monkeys (Chlorocebus aethiops) (n
= 15, age 5–10 years) were obtained from St. Kitts Island.
Monkeys were housed in an Assessment and Accreditation of
Laboratory Animal Care (AAALAC)-accredited facility under
the direct care of the Wake Forest School of Medicine Animal
Resources Program and euthanized at the termination of the
study. All experiments were approved by the Institutional Animal
Care and Use Committees of Wake Forest School of Medicine.
Monkeys were singly housed in climate-controlled conditions
with a 12 h light and dark cycle. The monkeys were provided
water ad libitum and were initially fed a weighed amount of a
chow diet (Monkey Diet 5038, Lab Diet) twice daily, such that
their daily caloric intake was 70 kcal day/kg body weight. During
the 10-week experimental diet feeding phase, the monkeys were
fed twice daily with a weighed amount of semi-synthetic diet
containing 0.002 (Lo), 0.2 (Med), or 0.4 (Hi) mg cholesterol/Kcal,
which was prepared at the Wake Forest Primate Center Diet
Laboratory. Daily caloric intake was 90 kcal/day/kg body weight.
Fecal samples were collected before and at the completion of
the 10-week experimental diet feeding and stored at −20◦C
until extraction.
Recovery From High-Fat Diet Study Design
Young adult male cynomolgus monkeys (Macaca fascicularis)
(n = 73) originated from Mauritius and at the onset of the
study were an average age of 5.3 years (range 4.2–6.7). The
monkeys were housed in an AAALAC-accredited facility under
the direct care of the University of Kentucky (UK) Division
of Laboratory Animal Resources (DLAR), and all experiments
were approved by the UK Institutional Animal Care and
Use Committee. Monkeys were housed in climate-controlled
conditions with a 12 h light and dark cycle and initially fed
ad libitum a standard non-human primate chow diet (Teklad
2050). The monkeys were then singly housed from ∼08:00–
15:00 each day and in the morning and afternoon, received
weighed portions of a semi-synthetic high-fat atherogenic
diet (Table 1), which provided on average 74 kcal/kg body
weight/day. After 20 months on the high-fat diet, monkeys
were switched back to standard chow diet and were treated for
6 weeks or 6 months with either vehicle (USP grade saline)
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TABLE 1 | Macronutrient composition as percent total calories.
High-Fat Diets Chow
Oleic High Medium Low Oleic Blend Recovery Study
Blend Cholesterol Cholesterol Cholesterol Study (5038) (2050)
Carbohydrates (%) 46 46 46 46 69 57
Protein (%) 17 16 16 17 18 29
Lipid (%) 37 38 38 37 13 14
Saturated (% lipid) 23 46 46 46 38 23
Monounsaturated (% lipid) 64 40 40 40 48 31
Polyunsaturated (% lipid) 13 19 19 19 14 46
or miR-33a/b antagonist RG428651, a 2′-fluoro/methoxyethyl-
modified, phosphorothioate (PS)-backbone-modified, antisense
oligonucleotide (ASO) (Regulus Therapeutics). Monkeys were
injected subcutaneously with vehicle or 5mg ASO/kg body
weight twice weekly during the first 2 weeks and then once weekly
during the remainder of the study. During the treatment period,
animals were singly housed from ∼08:00–15:00 each day and
received 12 biscuits of standard diet, which provided on average
64 kcal/kg body weight/day. Cecum samples were collected from
monkeys at completion of the 20-month high-fat diet and then
from monkeys that were switched to chow for 6 weeks or 6
months post high-fat diet.
Biliary Cholesterol Study Design
Male cynomolgus monkeys (Macaca fascicularis) (n = 12)
originated from China and at the onset of the study were an
average age of 3.6 years (range 3.8–3.4). The monkeys were
housed in an AAALAC-accredited facility under the direct care of
the University of Kentucky (UK) Division of Laboratory Animal
Resources (DLAR), and all experiments were approved by the UK
Institutional Animal Care and Use Committee. Monkeys were
housed in climate-controlled conditions with a 12 hr light and
dark cycle. The NHPs were fed a standard non-human primate
chow diet (Teklad 2050) for the first 4 weeks of treatment and
then switched to a high-fat/low cholesterol diet for the last 4
weeks of treatment. They were then singly housed from∼08:00–
15:00 each day and in the morning and afternoon, received
either 6 standard diet biscuits/feeding or weighed portions of the
high-fat/low cholesterol diet, which provided∼100 kcal/kg body
weight/day. Animals were injected subcutaneously twice a week
for 8 weeks with control antisense oligonucleotide (ASO) (n =
6; Ionis 141923) or Niemann-Pick C1-Like 1 (NPC1L1) ASO (n
= 6; Ionis 807400) at 20 mg/kg/dose. Feces were collected for 4
consecutive days during the 8th week of treatment and stored at
−20◦C until extraction.
Quantification of NPC1L1 mRNA
Total RNA was isolated from frozen liver and jejunum
using RNAzol Reagent (Molecular Research Center, RN190)
according to the manufacturer’s instructions. The concentration
of the RNA was determined using an ND-1000 UV-Visible
Spectrophotometer (Nanodrop). The integrity of the RNA was
verified by evaluating ribosomal RNA bands (28S/18S) separated
on a 1% denaturing agarose gel. Complementary DNA was
synthesized from 2 µg of total RNA using High-Capacity
cDNA Reverse Transcription Kit with RNase Inhibitor (Applied
Biosystems, 4374966). The cDNA was subjected to quantitative
real-time PCR reaction using TaqMan
TM
Fast Advanced Master
Mix (Applied Biosystem, 4444557) and TaqManGene Expression
Assay containing a set of PCR primers and a TaqMan probe
for cynomolgus monkey NPC1L1 and PAK1IP1 (Applied
Biosystem; 4351372, Assay ID: NPC1L1, Mf02793772_m1;
PAK1IP1, Mf02855023_m1). PCR was performed on Biorad
C1000 Touch Thermal Cycler with the following conditions:
95◦C for 30 s, followed by 40 cycles at 95◦C for 10 s and 57◦C
for 25 s. The relative amount of target gene was normalized
to the amount of PAK1IP1 (internal control) using the 2-
11CT method.
Lipid Homeostasis Study Design
The design of this study was previously described (31) as follows:
All experiments were approved by the WFUHS Institutional
Animal Care and Use Committee (IACUC). Male cynomolgus
monkeys (n = 16) were obtained from the Wake Forest
University breeding colony and were an average age of 2.0 years
(range 1.8–2.6). Animals were pair-housed when possible in
climate-controlled conditions with 12 h light/dark cycles. For
the combined LXR agonist (GW3965) and inducible degrader
of LDLR (IDOL) ASO treatment study, 16 monkeys were fed
a high-fat/moderate cholesterol diet (Teklad) for 4 weeks and
subcutaneously injected once during study week 1 with vehicle
(USP grade saline) or 40 mg/kg IDOL ASO (Ionis 549127; Ionis
Pharmaceuticals) and once during study weeks 2–9 with vehicle
or 30 mg/kg IDOL ASO. Starting on study week 8, monkeys
were fasted overnight, anesthetized as above, and gavaged with
10 mg/kg GW3965. The treatment regimen was conducted once
daily for 8 days. Feces were collected on 3 consecutive days during
study weeks 7 and 8 of ASO treatment.
Plasma Lipid and Lipoprotein
Concentration
For all previously mentioned studies, monkeys were sedated
following an overnight fast with ketamine (10 mg/kg
intramuscularly), and blood was collected in EDTA-containing
Vacutainer R© tubes. Plasma was isolated by centrifugation
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at 1,500 × g for 30min at 4◦C. Total plasma cholesterol
(Pointe Scientific, C7510) and triglyceride (Sigma, TR0100 &
F6428) concentrations were measured using enzymatic kits.
The cholesterol distribution among lipoprotein classes was
determined after separation by gel filtration chromatography
based upon the method described previously (32). An aliquot
of plasma from each animal was diluted to 0.5 µg total
cholesterol/µL in 0.9%NaCl, 0.05% EDTA/NaN3 and centrifuged
at 2,000 × g for 10min to remove any particulate debris. The
supernatant was transferred to a glass insert contained in
a GC vial. After loading the vial into an autosampler set at
4◦C (Agilent Technologies, G1329A), 40 µL of sample was
injected onto a Superose 6 10/300 (GE Healthcare Life Sciences)
chromatography column. Under the control of an isocratic
pump (Agilent Technologies, G1310A/B), the sample was
separated at a flow rate of 0.4 ml/min with eluent containing
0.9% NaCl, 0.05% EDTA/NaN3. The column effluent was mixed
with cholesterol reagent (Pointe Scientific, C7510) running at a
flow rate of 0.125 mL/min and the mixture was passed through
a knitted reaction coil (Aura Industries Inc., EPOCOD) in a
37◦C water jacket. The absorbance of the reaction mixture was
read at 500 nm using a variable wavelength detector (Agilent
Technologies, G1314F). The signal was subsequently integrated
using Agilent OpenLAB Software Suite (Agilent Technologies).
VLDL-C, LDL-C, and HDL-C concentrations were determined
by multiplying the plasma total cholesterol concentration by
the cholesterol percentage within the elution region for each
lipoprotein class.
Analysis of Hepatic Cholesterol
Frozen liver (∼50mg) was thawed, minced, and weighed in a
16 × 100mm glass screw-top tube with a Teflon lined cap.
Lipids were extracted in 3ml 2:1 chloroform/methanol at 60◦C
for 3 h and then at room temperature overnight. The lipid extract
plus a 2ml 2:1 chloroform/methanol wash of the extraction
tube was transferred to a new glass tube and dried down
under N2 at 60◦C. After the lipid was resuspended in 6ml 2:1
chloroform/methanol, 1.2ml 0.05% sulfuric acid was added, the
tube was vortexed, and the phases split by centrifugation at 1,500
× g at room temperature for 10min. The same volumes of 2:1
chloroform/methanol and 0.05% sulfuric acid were added to an
empty 15ml graduated glass tube to determine the volume of
the bottom phase. The aqueous upper phase was aspirated and
discarded, and an aliquot (typically 1ml) of the bottom phase
was transferred to a new glass tube using a glass volumetric pipet.
To the aliquot of the bottom phase was added 2ml 1% Triton X-
100 in chloroform, and the solvent was evaporated as described
above. Deionized water (1ml) was then added to the tube
which was capped, heated at 60◦C for 10min, and periodically
vortexed until the solution was clear. The samples and cholesterol
standards containing 2% Triton-X100 were analyzed for total
cholesterol (Pointe Scientific, C7510) and free cholesterol (Wako,
993-02501) using enzymatic assays conducted in 96-well plates.
Measurement of Cholesterol in Bile
Gall bladder bile (10 µl) was transferred to a 16 × 100mm
glass screw top tube with a Teflon lined cap containing 0.75ml
ddwater and 10 µg 5-alpha cholestane (Steraloids, C3300-
000). The following solutions were sequentially added to the
tube with vortexing for 20 s after each addition: (1) 2.25ml
2:1 methanol:chloroform, (2) 1.5ml chloroform, (3) 0.75ml
ddwater. The tube was centrifuged at 1,500 × g at room
temperature for 10min. After removing the top phase, a portion
of the bottom phase was transferred to a new glass tube and
evaporated under N2 at 60◦C. Ninety five percentage ethanol
(1ml) and 1ml 50% KOHwas added and the lipid was saponified
by incubating the tube at 60◦C for at least 60min. The following
solutions were sequentially added to the tube with vortexing
for 20 s after each addition: (1) 1ml hexane, (2) 1ml ddwater.
The tube was centrifuged at 1,500 × g at room temperature for
10min. The upper hexane phase was transferred to a 12× 75mm
glass tube and evaporated under N2 at 60◦C. The dried lipid was
dissolved in 50–100 µl hexane and transferred to a teardrop GC
vial insert. The neutral sterols were analyzed by injecting 1 µL of
sample onto a ZB50 (0.53-mm inner diameter × 15m × 1µm)
gas-liquid chromatography column (Phenomenex) at 250◦C and
installed in an Agilent Technologies 7890B gas chromatograph
equipped with a Agilent Technologies 7,693 autosampler using
on-column injection and a flame ionization detector.
Extraction of Fecal Bile Acids
Fecal bile acids were extracted as previously described with
minor modifications (33). Monkey fecal samples were weighed
(150–300mg each) in a glass tube. HPLC, or LC-MS grade
solvents were used throughout the extraction procedure
(FisherScientific). Samples were homogenized in 1ml of ethanol
containing 0.1N sodium hydroxide (Fisher Scientific) using
an Omni Tissue homogenizer (Omni International). Samples
were brought up to 5ml in ethanol and 0.5 nmol of internal
standard glycocholic acid (GCA; Sigma-Aldrich) was added to
each sample. Samples were placed in an 80◦C water bath for
1 h and then cooled on ice. Samples were centrifuged at 1,500
× g for 10min and supernatants were dried using an EZ-
2 Evaporator (Genevac). Dried samples were resuspended in
HPLC-grade water and then subjected to a solid-phase extraction
using a HyperSep-C18 cartridge (ThermoFisher). C18 cartridges
were preconditioned with methanol:chloroform mixture (2:1),
methanol and water. After loading the samples, cartridges were
washed with water, n-hexanes, and allowed to dry for 5min.
Samples were eluted in 1mL of methanol. Internal standard
recovery ranged from 70 to 90% and was used to calculate
extraction efficiency.
Fecal Neutral Sterol Analysis
After a 3–4 day quantitative collection of feces from singly housed
animals, water was added to the feces and total weight of the
mixture was determined. After making a fecal slurry using a
blender, an aliquot (∼100 µl) was transferred to a 16 × 100mm
glass screw top tube containing 100 µg 5-alpha cholestane
(Steraloids, C3300-000). After weighing the tube to determine
the exact weight of the fecal slurry aliquot, 2ml 95% ethanol
and 200 µl 50% KOH was added. The tube was sealed with a
Teflon lined cap and incubated at 60◦C for 3 h with periodic
vortexing. The following solutions were sequentially added to the
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tube with vortexing for 20 s after each addition: (1) 2ml hexane,
(2) 2ml ddwater. The tube was centrifuged at 1,500 × g at room
temperature for 10min. The upper hexane phase was transferred
to a glass GC vial and analyzed for coprostanol and cholesterol
levels with GC-FID as described elsewhere in the manuscript for
biliary cholesterol.
LC-MS/MS
Identification and quantification of bile acids was achieved by
LC-MS using an Ultimate 3,000 UHPLC liquid chromatography
system (ThermoScientific) equipped with a C18-PFP 1.7
um column (ACE Excel) paired to a TSQ Quantiva Mass
Spectrometer (ThermoScientific). Ten mM ammonium acetate
buffer (eluent A) and 75% acetonitrile, 25% methanol with
10mM ammonium acetate (eluent B) were used with a flow
rate of 0.325 ml/min. For detection of bile acids, a gradient
method was used starting at 26% eluent B for 5min, and
increasing to 98% eluent B by 25min. A wash step was performed
after each run using 100% methanol for 2min, followed by
equilibration in 100% eluent A for 5min. Ionization of the
samples was performed with the following settings: spray voltage,
3,500V; vaporizer temperature, 350◦C; sheath and auxiliary
gas (nitrogen) pressure, 20 and 2 arbitrary units, respectively;
ion transfer capillary temperature, 300◦C; collision gas (argon)
pressure, 1.5 mTorr; collision energy 10–55V; and ion polarity,
negative. Selected reaction monitoring (SRM) was conducted
using the characteristic precursor-to-product ion transition and
retention times. Sample (1 uL) was injected into the LC-MS by
autoinjector. Bile acid retention time was determined empirically
using pure standards of each bile acid. Bile acid concentrations
in samples were determined using standard curves for each
bile acid.
DNA Extraction
The majority of the samples were extracted with a protocol
suitable for tough environmental samples because they contained
a large amount of fibrous material. The protocol used a
combination of bead beating and chemical lysis with a
chloroform precipitation. Samples were lysed in 1ml extraction
buffer [100mM Tris-HCl (pH 8.0), 100mM EDTA disodium salt
(pH 8.0), 100mM sodium phosphate (pH 8.0), 1.5M sodium
chloride and 1% CTAB], 20 µl of proteinase K (10 mg/mL),
and 25 µl of SDS (20%) using bead beating (0.25 g each of
0.1mm and 0.5mm glass beads) for 15min on a horizontal vortex
adaptor (MO BIO Laboratories, Carlsbad, CA) at full speed.
Then, the samples were incubated at 60◦C for 30min with gentle
end-over-end inversions by hand at the midpoint of 15min;
750 µL of supernatant was collected in a new microcentrifuge
tube after centrifugation at 6,000 × g for 10min. DNA was
separated from organic debris with a chloroform: isoamyl alcohol
(24:1 vol/vol) extraction and precipitated overnight at −20◦C
using isopropanol. Samples were removed from the −20◦C and
warmed to 37◦C to dissolve salt precipitates, and the DNA was
pelleted at 15,000 × g for 30min. Finally, the DNA pellet was
washed twice with ice cold 70% ethanol and dissolved in 50 µL
ultrapure water (NANOpure IITM, Thermo Scientific, Waltham,
MA, USA) water. The Recovery study samples were received at a
later date and processed using methods developed for the NIH-
Human Microbiome Project (34). DNA was extracted from feces
using a MoBio Power Soil DNA extraction kit (MoBio, Carlsbad,
CA) with added incubation at 65◦C after blandk step as suggested
for human samples.
Library Preparation and Sequencing
Methods were used following the NIH-Human Microbiome
Project (34). The V4 hypervariable region of 16S ribosomal
RNA gene was amplified with barcoded primers [515f and 806r,
(35)] in triplicate using the 5 PRIME HotMasterMix (VWR).
Products were quantified with Quant-iT TM PicoGreen R©
dsDNA Assay Kit (Thermo Fisher) and samples were combined
in equal amounts (∼250 ng per sample) to be purified with the
UltraClean PCR R© Clean-Up Kit (MO BIO). Pooled amplicons
were sequenced on the Illumina HiSeq 2,500 platform to generate
150bp single end reads.
Data from each study was processed individually to preserve
their characteristics using Quantitative Insights Into Microbial
Ecology (QIIME) software package version 1.9.1 (36). De-
multiplexed and quality-controlled sequences were binned using
open picking (37) with SUMACLUST (38, 39) into OTUs at
97% similarity using UCLUST against a Greengenes reference
database using the pick_closed_reference_otus.py script (40,
41). Singletons and OTUs representing <0.005% total relative
abundance were removed. Post-quality filtering and removing
OTUs representing <0.005% of all OTUs were preformed to
reduce the sparsity of the dataset, and a rarefied (42, 43) dataset
was used in certain downstream analyses. The Oleic Blend Study
had an average of 84,099 reads per sample and were rarified
to 35,727 reads, which removed 1 of 30 samples. The Recovery
Study had an average of 151,575 reads per sample and were
rarified to 78,088 reads, which removed 2 of 96 samples. The
Biliary Cholesterol Study had an average of 158,769 reads per
sample and were rarified to 62,854 reads, which removed 0 out
of the 32 samples. The Lipid Homeostasis Study had an average
of 130,024 reads per sample and were rarified to 97,462 reads,
which removed 1 of 12 samples.
Statistical Analyses
Microbiome communities were visualized using unweighted
UniFrac (44) with principal coordinates analysis (PCoA) using
the phyloseq package (45). Differences among groups were
tested using non-parametric multivariate analysis of variance
(PERMANOVA) (46) by the adonis function (47). Alpha diversity
was calculated using Shannon Diversity index, which takes into
account richness and evenness, that is, if few taxa dominate the
community or many taxa are evenly represented. Differential
abundance was determined on non-rarefied data as suggested
(42, 43) and normalized by size factors estimated by the median-
of-ratios method using a negative binomial Wald Test that
uses standard maximum likelihood estimates for Generalized
Linear Model coefficients DESeq2 R package (48). P-values were
corrected for multiple comparisons using Benjamini-Hochberg
method and alpha was set to 0.01 using the. Analysis of
variance (ANOVA) using Tukey post-hoc tests as a correction for
multiple comparisons was used to detect significant differences in
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measured physiological traits. Bile acid data were analyzed with a
two-way ANOVA accounting for the two treatments.
Data Accessibility
The datasets analyzed for this study can be found in the NCBI
Sequence Read Archive under accession number PRJNA701533
(Oleic Blend), PRJNA714188 (Recovery), PRJNA707361 (Lipid
Homeostasis), and PRJNA713505 (Biliary Cholesterol).
RESULTS
Overview of Studies
Feces and cecal samples were collected from previously
completed NHP studies that utilized various treatments to
influence plasma lipid levels (Figure 1). The studies were not
designed to specifically test the effects of diet or pharmacological
treatments on the microbiome, but their availability allowed
us to investigate the relationship between the gut microbiome
and host lipid metabolism. The high-fat diet Oleic Blend
(HFD-OB) study was utilized to determine the effect of a
monounsaturated fat rich diet in the context of three cholesterol
levels in contrast to a chow diet. The Recovery study investigated
changes that occur after being on a high-fat diet with high
cholesterol (0.4% w/w or 1 mg/kcal) (HFD-HC) for a long
period of time (20 months) and then during a chow recovery
period with an anti-miR-33 or vehicle treatment. Targeting this
microRNA was intended to increase HDL levels and improve
cholesterol efflux (49), and consequently stimulate regression or
stabilization of atherosclerotic lesions in the NHPs. Regardless
of treatment type, switching animals from HFD-HC to chow
diet resulted in a significant reduction in plasma total cholesterol
(Supplementary Figure 1A). In contrast, anti-miR-33 compared
to vehicle treatment significantly increased HDL cholesterol
(Supplementary Figure 1B). The Biliary Cholesterol Study used
a Niemann–Pick C1-Like 1 (NPC1L1) antisense oligonucleotide
(ASO) throughout the duration of the study which we
hypothesized would inhibit NPC1L1-mediated transport of
biliary cholesterol into hepatocytes thereby decreasing hepatic
and plasma cholesterol concentrations. The study design
consisted of first a chow diet and then high-fat diet with
low cholesterol (0.04% w/w or 0.1 mg/kcal) (HFD-LC). We
found that NPC1L1 ASO treatment specifically decreased
NPC1L1 gene expression in the liver resulting in modest
reductions in hepatic and plasma but not biliary cholesterol
(Supplementary Figure 2). Since bile acid concentration in gall
bladder bile was also unchanged (data not shown), reducing
hepatic NPC1L1 expression in liver does not appear to decrease
the intracellular cholesterol pool to the point where bile
acid synthesis and pool size would be diminished. The Lipid
Homeostasis study used a high-fat diet with low cholesterol
(0.05% w/w or 0.12 mg/kcal) (HFD-MC) for the duration of the
study, but it also included ASOs for IDOL and LXR agonist.
LXR agonist treatment of the cynomolgus monkeys increased
LDL cholesterol due to increased hepatic IDOL and consequent
degradation of LDL receptor protein (31). Treatment with the
IDOL ASO resulted in partial knockdown of the expression of
IDOL in the liver and significantly blunted the LXR agonist-
mediated increase in LDL cholesterol (31).
Other details including monkey species and timescales were
different between the studies. The high-fat diet oleic blend (HFD-
OB) study was unique in that the primates were Chlorocebus
aethiops (African green) and the high-fat diet was atypical. The
remaining three studies used Macaca fascicularis (cynomolgus)
primates with similar high-fat diet compositions and included
treatments that influenced host gene expression related to
cholesterol and lipid metabolism. The Recovery study was
conducted over 2 years (Figure 1), but the other studies were
completed within 9–20 weeks.
Each study contained a high-fat diet as part of the
study design. The macronutrient levels were similar at 46%
carbohydrates, 16–17% protein, and 37–38% fat (Table 1), but
the lipid profile and components differed (Table 2). The high-
fat diet oleic blend (HFD-OB) was 23% saturated fat, 64%
monounsaturated fat, and 13% polyunsaturated fat, (Table 1)
and was comprised of cocoa butter, palm, sunflower, safflower,
and soybean oil (Table 2). There were also three levels of
cholesterol: high (0.4mg cholesterol/kcal), medium (0.02mg
cholesterol/kcal), and low (0.002mg cholesterol/kcal). This oleic
blend was created to determine the impact of a monounsaturated
fat rich diet on atherosclerosis development in an African green
monkey model. The fat source in the other diets was lard, and
the composition was 46% saturated fat, 40% monounsaturated
fat, and 19% polyunsaturated fat (Table 1). There were only two
studies, HFD-OB and Recovery, able to compare high-fat diets to
chow, and the chow diets did not have the same macronutrient
levels or composition (Table 1).
Different High-Fat Diets With Opposite Diet
Timing Similarly Affect the Microbiome
The contrasting effects between a high-fat and chow diet on the
microbiome were more influential than the timing of the diet
and the high-fat diet composition. The HFD-OB and Recovery
studies both had high-fat and chow diets, but that is the only
constant between them. All diets had different compositions, the
time scale was weeks vs. months, and the diet orderings were
opposite. The HFD-OB was a typical design where the chow diet
was followed by a high-fat diet and each diet was fed for 10 weeks.
The Recovery study started with 20 months of a high-fat diet,
and then was followed by a chow diet for 6 weeks in trial 1 or
6 months in trial 2. Even with all of these differences, the effect
of a high-fat diet similarly altered the community composition,
visible in the principal coordinates analysis with Weighted
UniFrac distance (Figures 2A,B). Significant clustering was
determined by non-parametric multivariate analysis of variance
(PERMANOVA) because it is sensitive to differences in group
dispersion and location in the ordination, and therefore it is able
to distinguish if groups are distinctly different. Both Recovery
trials were included in the analysis because they were not
significantly different (PERMANOVA, P = 0.135); however, the
chow diet communities were different at 6 weeks vs. 6 months
(PERMANOVA, P = 0.008) indicating a long-term response to
coming off a high-fat diet. The effect of a high-fat vs. chow
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FIGURE 1 | Overview of study designs, treatments, and diet compositions.
diet changed the microbiome community structure regardless of
which diet was applied first, and the microbiome was still altered
6 months after switching from a high-fat to a chow diet.
Shifts in the microbiome due to diet were consistent. Alpha
diversity (Shannon Index) and the Firmicutes/Bacteroidetes
(log2) ratio were significantly decreased in the high-fat diets
(Figures 2C,D) determined byMannWhitney non-parametric t-
test or non-parametric Kruskal-Wallis ANOVA. These values still
continued to increase 6 months post high-fat diet indicating that
the community had not yet reached equilibrium (Figure 2D).
The long-term response of the microbiome to dietary changes
has been noted in both mice (50) and humans (51). We may
have expected the F/B ratio to increase on a high-fat diet
because higher values have been associated with obesity (52),
but the levels decreased in this instance. It is important to
note that the animals did not become obese because they were
fed controlled amounts of diet. We observed differences in the
levels between studies, but this may be a result of different
extraction methodologies. The Recovery study samples were
processed at a later date using the protocols of the Human
Microbiome Project while the HFD-OB study utilized a protocol
consisting of a combination of bead sizes with chemical lysis
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TABLE 2 | Diet composition of high-fat diets.
Description Ingredient High-Fat Diet Composition (g/100g)
Oleic Blend High Cholesterol Medium Cholesterol Low Cholesterol
Carbohydrate Dextrin 9.6 9.6 9.6 9.6
Sucrose 10 10 10 10
Wheat Flour, self-rising 35 35 35 35
Protein Casein, USP 9 9 9 9
Lactalbumin 5 – – –
Fonterra Whey Protein Isolate-895 – 5 5 5
Lipid ACHumko Oleic Blend* 16.4 – – –
Lard – 16.4 16.4 16.4
Fish Oil (Omega Protein) 0.2 – 0.2 –
Menhaden Oil (Omegapure) – 0.2 – 0.2
Crystalline Cholesterol 0, 0.08, 0.16 0.39 0.027 0.039
Fiber Alphacel 7.3 6.5 7.3 6.5
Vitamins Vitamin Mixture, Teklad * ** *** 2.5 2.5 2.5 2.5
Mineral Salts Hegsted Salt Mixture (Ca, P, Mg, Zn, Cu) 5 5 5 5
Plant Sterol Beta-sitosterol (ICN) 0.0068 – – –
Antioxidant Tenox 20A 0.008 – 0.008 –
Vitamin E MTS-50 (NLT 50% total tocopherols, NMT 20%
d-alpha tocopherol, oil)
0.012 – – –
Vitamin E Vit E 5–67 0.004 – – –
Calcium Carbonate – 0.4 – 0.4
* Complete Vitamin Mixture (BGSM formula) made by Teklad.
** Complete Vitamin Mix includes 0.0625ml of D3 in Corn Oil for each 100 grams of diet ingredients.
(6.25 ml/10,000 gram batch of diet), to provide 2.5 IU of D3 per gram of diet.
*** All Calcium Phosphate Tribasic and Potassium Phosphate Dibasic was removed and replaced with Potassium Carbonate and Dextrin.
Water - 2000 ml/10,000 gm batch dry ingredients (3.36 Cal/gm wet diet).
Feed monkeys 100−120 Calories per kg body weight per day + 10% waste.
that is suitable for tough environmental samples (53). It has
been noted that extraction methods without multiple sizes of
small beads underrepresent Firmicutes from a lack of lysis
(personal communication, Zymo Inc.), and our data follows
that pattern. Even with all of these differences, high-fat diets
decreased diversity and F/B ratio regardless of diet composition
and order indicating that these factors are outweighed by a
macronutrient shift.
Phyla taxonomic level shifts were variable between the
two studies. Differentially abundant phyla between diets were
determined by DESeq2 using monkey age, treatment, and trial
when applicable as covariates. The high-fat diet samples from
the two Recovery study trials were combined and analyzed
as one because there were no significant differences between
them (PERMANOVA, P = 0.3). Increases in Bacteroidetes and
Proteobacteria in the high-fat diets were the two consistent
significant results (Figures 2E,F). Actinobacteria was greater
in HFD-OB (Figure 2D) while Fusobacteria was greater in
HFD-HC (Figure 2F). Decreases in phyla relative abundance
on the high-fat diets were seen in Euryachaeota (11–0.7%)
and Cyanobacteria (0.5–0.008%) in the Recovery study and
Synergistetes, Tenericutes, and Firmicutes in the Oleic Blend
study. All of these phyla, except for Firmicutes, represented
<12% of the total relative abundance.
When analyzed at the OTU level, more taxa shifted in the
same direction based on diet than not. Overall, the Recovery
study had more significantly different OTUs at 329 vs. 195
OTUs in the Oleic Blend study. Thirty-three of these OTUs
were common between the studies and 25 were consistent in
which diet they were more abundant. The OTUs were averaged
at the genus level to determine relevant taxa that were associated
with the diets (Figure 3). In both studies, Bulleidia, Clostridium,
Ruminococcus, Eubacterium, Coprocacillus, Lachnospira, Blautia,
Coprococcus, and Oscillospira were greater in chow while
Succinivibrio, Collinsella, Streptococcus, and Lactococcus were
greater in high-fat diets. Dorea, Prevotella, Faecalibacterium,
Lactobacillus, and Aggregatibacter had disparate results between
the two studies. One difference between the studies is the
proportion of significantly different genera that were greater in
the high-fat diet where 54% (22/41) of the identified genera
were in the Recovery high-fat diet and 15% (13/37) were in
the Oleic Blend high-fat diet. The numbers followed the trend
that whatever diet was received first had more significantly
identified genera.
Treatments That Did Not Affect the
Microbiome
Various treatments were employed to alter plasma lipid levels
and the microbiome was unresponsive to these. There was
no distinct pattern of dietary cholesterol level associated with
the microbiome community (Figure 4A) in the Oleic Blend
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FIGURE 2 | Microbiome changes between high-fat diets and chow are similar even with different diet composition and order. Left panels are the High-fat diet Oleic
Blend study and right panels are the Recovery from a High-fat diet study. Ordinations (A, B) were plotted using principal coordinate analysis with weighted Unifrac
distance, and groups were compared using non-parametric multivariate analysis of variance (PERMANOVA). Dashed ellipses represent 95% CI from the cluster
(Continued)
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FIGURE 2 | centroid. Microbiome characteristics of alpha diversity (Shannon) and Firmicutes/Bacteroidetes Ratio (log2) were tested with Mann Whitney
non-parametric t-test (C) or non-parametric Kruskal-Wallis ANOVA (D). Differentially abundant phyla between diets were determined by DESeq2 using age and
treatment as covariates and are bolded and italicized (E). The two chow time points were combined for the RA study and time was added as a covariate in
analyses (F).
FIGURE 3 | Differentially abundant taxa between high-fat and chow diets show overall consistency with a few disparate results. Significantly different OTUs are named
by their genus level and were determined by DESeq2 using age and treatment, and time when applicable, as covariates. Colors for (A) High-fat Oleic Blend study and
(B) Recovery from High-fat Diet study are ordered chronologically to represent which diet was received first. The HFD-OB contained three different levels of cholesterol
and were combined for analysis because there were no significant differences between them. Colored taxa names refer to which treatment the abundance was higher.
Taxa that have consistent trends between the two studies are bolded, italicized, and underlined, and taxa that have opposite trends are designated with an asterisk.
study, but it did affect plasma total cholesterol (ANOVA, P
= 0.001) and LDL (ANOVA, P = 0.0003) levels. The anti-
miR-33 treatment was included during the chow period (6
weeks or 6 months) of the Recovery study, and it had no
discernible effect on the microbiome (Figure 4B). The only
plasma lipid that responded to the miR-33 ASO was HDL
cholesterol, which significantly increased (T-test, P = 0.0002;
Supplementary Figure 1). In the Biliary Cholesterol study, the
NCP1L1 ASO was administered for the duration of the study.
It modestly but significantly decreased plasma lipid and hepatic
total cholesterol (Supplementary Figure 2), and showed a slight
effect on the microbiome that is visible along Axis 3 in the
PCA (Figure 4C). This axis represents only 3.7% of the variation,
and the groups were not significantly different in the PCA
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plot (PERMANOVA, P = 0.9). The IDOL ASO of the Lipid
Homeostasis Study was administered for 8 weeks and also had
no influence (PERMANOVA, P = 0.141) on the microbiome.
These results indicate that there is minimal or no relationship
between host regulation of lipid levels through miR-33, NPC1L1,
and IDOL and the microbiome.
LXR Agonist Modifies the Microbiome
One pharmacologic manipulation that altered the microbiome
is the LXR agonist in the Lipid Homeostasis study. After 7 days
of treatment, significant changes (PERMANOVA, P = 0.005) in
the community were distinctly visible along Axis 3 in the PCA
with Weighted UniFrac (Figure 5A). No significant differences
were calculated by MannWhitney non-parametric t-test in alpha
diversity (Shannon; P = 0.42) and the Firmicutes/Bacteroidetes
(log2) ratio (P = 0.70), but there were differences in specific
taxa. Proteobacteria significantly increased (P < 0.0001) with
the LXR agonist determined by DESeq2 using age and treatment
as covariates, as did Synergistetes, but this phylum represented
only 0.01% total relative abundance (Figure 5B). The phyla that
significantly decreased with the LXR agonist were Fibrobacteres,
Spirochaetes, and WPS-2, and these were also minimally
abundant taxa representing 0.02, 0.16, and 0.04% total relative
abundance, respectively (Figure 5B). When comparing at the
OTU level, 106 OTUs were significantly different where 46
(representing 7 genera) were reduced and 61 (representing 15
genera) were increased with the LXR agonist. Fifty-four were
described at the genus level, and OTUs within the same genus
were averaged to determine the relative abundance (Figure 5C).
Also, this treatment increased plasma total cholesterol (t-test, P
= 0.0006) and LDL cholesterol (t-test, P = 0.002) levels (54),
but not fecal cholesterol (t-test, P = 0.7), fecal coprostanol
(t-test, P = 0.2), or fecal cholesterol excretion rate (t-test, P
= 0.1) There is no known relationship between LXR and the
microbiome, but LXR influences the conversion of cholesterol
into bile acids by modulating a rate limiting step of cholesterol
7α-hydroxylase levels (55). Based on genomic profiling of
bile salt hydrolase (BSH) genes in human gut microbiome
communities (56), only 15% (7/29) of the OTUs that were
increased in the Pre-LXR treatment may have had BSH activity
while 46% (28/61) of the OTUs that were increased in the LXR
agonist are in genera known to have BSH activity. In contrast,
the Firmicutes phylum was decreased with the LXR agonist,
which was the phylum that contained 59.73% of the surveyed
BSHs (56). These observations cannot be tested statistically
and would need further analyses to determine if there was
a difference in BSH activity in response to the LXR agonist.
The BSH containing genera of the OTUs increased in the pre-
LXR treatment were Ruminococcus, Lactobacillus, Streptococcus,
and Treponema, while the OTUs that increased in the LXR
agonist were Acinetobacter, Ruminococcus, Faecalibacterium,
Pseudomonas, Streptococcus, Coprococcus, and Enterococcus,.
Only Ruminococcus and Streptococcus were present in both
groups while the other genera were unique. These results suggest
that bile acids could be indirectly responsible for a microbiome
response to increased LXR activity.
FIGURE 4 | Treatments with no or minimal effect on the microbiome. Results
were plotted using principal coordinate analysis with weighted Unifrac
distance, and groups were compared using non-parametric multivariate
analysis of variance (PERMANOVA). There was no effect in the (A) High-fat
Oleic Blend study due to dietary cholesterol level and in the (B) Recovery from
High-fat Diet study due to Anti-miR-33. There was a slight effect in the (C)
Biliary Cholesterol study from NPC1L1 visible on Axis 3. Large ordinations
represent samples enclosed in the bolded boxes of the thumbnail ordinations.
Dashed ellipses represent 95% CI from the cluster centroid.
LXR Agonist Decreases Fecal Bile Acids
Bile acid levels in the feces were measured before and after
the LXR agonist. A total of nine bile acids were detected. The
primary bile acids cholic acid (CA) and glycochenodeoxycholic
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FIGURE 5 | The Lipid Homeostasis Study used IDOL ASO and LXR Agonist as treatments, and only the LXR Agonist affected the microbiome. Samples were plotted
using principal coordinate analysis with weighted Unifrac distance, and groups were compared using non-parametric multivariate analysis of variance (PERMANOVA)
Dashed ellipses represent 95% CI from the cluster centroid. (A) Differentially abundant phyla between diets were determined by DESeq2 using age and treatment as
covariates and are bolded and italicized (B), and differentially abundant OTUs were described at the genus level (C). Legend colors are listed in order corresponding to
the ordering with the bars. If colors are missing, then the relative abundance values are too small to be visible. Colored taxa names refer to which treatment the
abundance was higher.
acid (CDCA) are synthesized from cholesterol by the liver. The
secondary bile acids deoxycholic acid (DCA), lithocholic acid
(LCA), hyodeoxycholic acid (HDCA), and ursodeoxycholic acid
(UDCA) are a result of bacterial modifications that occur in the
gut. Taurodeoxycholic acid (TDCA) and taurolithocholic acid
(TLCA) are derivatives of the secondary bile acids DCA and LCA,
respectively, that are absorbed by the host and then conjugated
with taurine in the liver. The undefined bile acid 3b7a12a is an
isomer of cholic acid. The most abundant bile acids were the
bacterially derived DCA and LCA. Two genera were correlated
to fecal bile acids using non-parametric Spearman correlation.
Pseudomonas was negatively correlated to DCA (rho = −0.72,
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FIGURE 6 | The LXR agonist decreased fecal bile acids. Data were analyzed with a two-way ANOVA for IDOL ASO and LXR Agonist treatments. There were no
significant differences due to IDOL ASO, and the p-values plotted refer to the effect of the LXR treatment.
P = 0.006), CA (rho = −0.72, P = 0.006), total bile acids (rho =
−0.68, P = 0.01), and 3b7a12a (rho = −0.63, P = 0.006), while
Ruminococcus was positively correlated with TLCA (rho = 0.65,
P = 0.03) and TDCA (rho= 0.63, P = 0.03). In general, the LXR
agonist decreased fecal bile acid levels, and data was analyzed
with a two-way ANOVA to account for the IDOL ASO and LXR
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agonist treatments (Figure 6). There was no significant effect of
the IDOLASO on any bile acids, but the LXR agonist significantly
decreased total bile acids by two-thirds from 225± 140 (nmol/g)
to 86 ± 43 (nmol/g) (P = 0.01). A significant decrease was also
observed in all individual bile acids except GCDCA and UDCA
(Figure 6). Bile acids in the gallbladder were measured, but all
primates were on the LXR agonist treatment at study completion
(Figure 1), therefore we were unable to compare pre- and post-
LXR treatment. However, there were no significant differences
due to the IDOL ASO on biliary bile acids. It is clear from these
results that the LXR agonist decreases levels of bile acids in feces.
DISCUSSION
The compilation of these four studies refines the complex
relationship between the microbiome and plasma lipid levels.
The dietary influence on the microbiome is apparent and
related to the macronutrient levels. The specific fat composition
and cholesterol levels were not significant in this instance.
Pharmacological treatments that influenced host lipid levels
but not the microbiome included ASOs targeting miR-33,
NPC1L1 and IDOL. This suggests that plasma lipid levels
do not have a substantial direct effect on the microbiome
whereas the microbiome can indirectly affect lipid levels (57, 58).
One potential mediator between plasma lipid levels and the
microbiome is bile acids. Our study shows that LXR agonist
treatment shifted themicrobiome. LXR affects bile acid levels and
bile acids are toxic to bacteria and can shift the microbiome. This
suggests that the indirect relationship between microbiome and
plasma lipid levels is mediated by bile acids.
High-fat diets are known to shift gut microbe taxa levels
and decrease diversity (59). Our results follow this pattern, even
when the diet order is reversed, that is, where the high-fat diet
is followed by the chow diet. Few studies have investigated this
recovery of the microbiome after high-fat diets. When studied in
mice, it took five times longer than the high-fat diet perturbation
for themicrobiome to revert back to a community resembling the
normal chow (50). We observed that when placed on chow after
a high-fat diet, communities remained different between 6 weeks
and 6 months, and it is likely that the 6 month community was
not yet at equilibrium. Mice were able to recover taxa suppressed
by a lowmicrobial accessible carbohydrate diet, which is inherent
to a high-fat diet, but these were lost to the next generation (20).
The time scale for the mouse study was weeks and it is unknown
if 20 months of HFD consumption could cause eradication of the
taxa that utilize the carbohydrate component of chow diets.
The Firmicutes/Bacteroidetes ratio has been utilized as a
metric to describe the microbiome community and higher levels
have been associated with high-fat diets (60) and obesity (52, 61,
62), but the pattern has not always held true in humans (63).
We found that the ratio decreased on the high-fat diets, and
this was opposite to trends previously observed in two different
monkey studies. African green monkeys were fed a similar high-
fat diet (protein- 18%, fat- 37%, carbohydrate- 45%, fiber-9%)
and had an increased F/B ratio in contrast to decreases seen in
humans (64). It is likely a factor other than fat level is driving
the F/B ratio because higher levels were associated with wild
populations in red-shanked doucs (Pygathrix nemaeus), with
levels decreasing as the degree of captivity increased (65). Also,
when comparing a western and Mediterranean diet that had
nearly identical macronutrient levels in cynomolgus macaques
(Macaca fascicularis), the F/B ratio was higher in the Western
diet (66). The difference between theWestern andMediterranean
diets was in saturated fat level (39 vs. 25%), monounsaturated
fat (35 vs. 50%), omega 6:3 ratio (15:1 vs. 3:1), and fiber (9
vs. 13%) (66). This indicates that the ratio may be responding
to specific nutrients that inherently change in chow compared
to high-fat diets and it is not necessarily the difference in
macronutrient levels.
Many of the identified taxa have been detected in other studies.
A decrease in Clostridium and an increase in Collinsella were
observed in both our high-fat diets and with African green
monkeys on a similar macronutrient ratio Western diet (64). In
the same study, an increase in Cantenibactium and Desulfovibrio
was observed (64), but in our studies this only occurred in the
Recovery one. Prevotella increased in their Western diet (64)
similarly in our Recovery study but in contrast to the Oleic Blend
study. In a study comparing Western diet to Mediterranean diet
in cynomolgus macaques (66), a decrease in Clostridium and
Oscillospira and an increase in Coprococcus was also observed
in congruence with both our studies. However, an increase
in Ruminococcus on their Western diet was opposite to the
decrease in our studies, and a decrease in Lactobacillus and
Faecalibacterium was only observed in the Recovery study. In
addition, a meta-analysis using rodent and human data found
that an increase in Lactococcus was the most reproducible result
when comparing high-fat to chow diets (60), and this taxon was
increased in both our high-fat diets.
The pharmacological ASO treatments used in this study were
administered to alter plasma lipid levels of the host, and the
negative results indicate that this regulation is not dependent
on the microbiome. Anti-miR-33 treatment was deployed to aid
recovery from a high-fat high-cholesterol diet because it increases
HDL levels and reduces atherosclerotic plaque burden (49). The
microbiome has been associated with plasma HDL levels (14),
but we did not find any significant correlations, possibly because
our study was underpowered. Transgenic expression of NPC1L1
in mouse liver results in significantly reduced biliary cholesterol
and increased total plasma cholesterol (67); therefore it was
hypothesized that ASO-mediated knockdown of hepatic NPC1L1
expression would increase biliary cholesterol and reduce plasma
cholesterol. While hepatic knockdown of NPC1L1 was associated
with modest but significant decreases in liver and plasma total
cholesterol, the anticipated increase in biliary cholesterol was not
found. A slight effect on the microbiome was observed with the
NPC1L1 ASO, which could reflect differences in bile acid pool
size or composition, which were not measured for this study.
The IDOL ASO was used to prevent hyperlipidemia because
it reduces IDOL expression and consequently increases LDL
receptor, which is responsible for the clearance of LDL by the
liver and other tissues (54). This treatment had no effect on the
microbiome, and further supports that plasma lipid levels do not
influence microbiome composition.
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The one pharmacologic manipulation that did affect the
microbiome was the LXR agonist. An effect was observed at
7 days, and this quick response was also seen in a different
LXR study in cynomolgus monkeys (68). LXR activation has
been shown to decrease cholesterol 7α-hydroxylase (CYP7A1),
which is the rate limiting enzyme for conversion of cholesterol
to primary bile acids (55) in human cells (69) and possibly
African green monkeys (70). This would lead to a reduction
of bile acid production and lowered lipid levels (68), which we
observed. It is important to note that this is not the case in
mice (68), which highlights the difference between species in
relation to bile acids and lipid levels. In addition, the same LXR
agonist was shown to increase inflammation in colonic cells
through ATP-binding cassette transporter (ABCA1) (71). This
transporter is also known as the cholesterol efflux regulatory
protein (CERP) and influences cellular cholesterol levels. Since
this treatment in our study affected fecal bile acid levels but not
fecal cholesterol levels, we believe bile acids are related to the
microbiome changes.
Bile acids are toxic to bacteria, and bile salt hydrolases
are a conserved adaptation that removes taurine and glycine
conjugations from bile acids making them more tolerable (72)–
. Bacterial enzymes can also further modify bile acids to
secondary bile acids through dehydroxylation, dehydrogenation,
and epimerization reactions (26). These modified bile acids can
then be reabsorbed and act as signaling molecules affecting
multiple pathways of host metabolism (28). Two important
receptors of these signals are nuclear farnesoid X receptor
(FXR) and the G protein-coupled membrane receptor 5 (TGR5),
and both of these are important to cardiovascular risk (29).
These receptors have been discussed as a mechanistic route
for bile acids affecting host lipid levels, but LXR has not
been previously investigated (73). These results suggest that
bile acids could shift the microbiome due to a manipulation
of host lipid metabolism and that LXR may be another
mechanistic route.
In summary, this compilation of non-human primate studies
demonstrated that manipulations of host lipid levels through
pharmacologic and dietary techniques may indirectly affect the
microbiome through altered host bile acid regulation. High-
fat diets compared to chow diets altered the microbiome
in a consistent manner through decreased Shannon diversity
and F/B ratio even when the fat sources were lard vs. a
high oleic blend and the diets were applied in opposite
orders. The relationship between host lipid levels and the
microbiome has mostly been demonstrated through correlations
and the mechanisms have remained unknown. We were
unable to associate microbiome taxa with lipid levels due
to power constraints, but we showed that pharmacological
treatments of miR-33, NPC1L1, and IDOL ASO and dietary
cholesterol did not affect the microbiome. The one treatment
that did affect the microbiome was an LXR agonist and
this may be through altered bile acid synthesis. Two genera,
Pseudomonas and Ruminococcus, were correlated with various
bile acids. These results indicate that the relationship between
host lipid metabolism and the gut microbiome is likely
indirectly regulated through the production of bile acids
from cholesterol.
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Supplementary Figure 1 | Total and HDL cholesterol in NHPs from the Recovery
from High-Fat Diet Study. Fasting plasma was isolated from male cynomolgus
monkeys that were exclusively fed HFD-HC for 20 months (HFD-HC n = 24) or
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and concomitantly treated with vehicle (6 weeks n = 13, 6 months n = 12) or
miR-33 ASO (6 weeks n = 13, 6 months n = 12). Data for total cholesterol (A) was
analyzed using Kruskal-Wallis test and Dunn’s multiple comparisons test while that
for HDL cholesterol (B) was analyzed using ordinary one-way ANOVA and Tukey’s
multiple comparisons test. Data not sharing a common letter differ significantly
(p ≤ 0.02).
Supplementary Figure 2 | Effects of NPC1L1 ASO on male cynomolgus
monkeys in the Biliary Cholesterol study. (A) NPC1L1 mRNA in liver and small
intestine. Data is graphed as relative expression (RE) to NPC1L1 in liver from
vehicle treated animals. Liver data was analyzed using unpaired t-test and
intestinal data was analyzed using Mann-Whitney test. (B) Cholesterol
concentration of gall bladder bile. Data was analyzed using unpaired t-test. (C)
Total and free cholesterol in liver. Data was analyzed using unpaired t-test. (D–I)
Plasma cholesterol, LDL cholesterol and HDL cholesterol graphed as
concentration (mg/dl) or percent change from baseline (Treatment Week 0). Data
was analyzed using 2-way RM ANOVA, p-value for Time x Treatment.
Frontiers in Medicine | www.frontiersin.org 15 August 2021 | Volume 8 | Article 646710
Lang et al. Diets, Lipids, and Primate Microbiome
REFERENCES
1. Antharam VC, Li EC, Ishmael A, Sharma A, Mai V, Rand KH, et al.
Intestinal dysbiosis and depletion of butyrogenic bacteria in clostridium
difficile infection and nosocomial diarrhea. J Clin Microbiol. (2013) 51:2884–
92. doi: 10.1128/JCM.00845-13
2. Petersen C, Round JL. Defining dysbiosis and its influence on host immunity
and disease. Cell Microbiol. (2014) 16:1024–33. doi: 10.1111/cmi.12308
3. Halfvarson J, Brislawn CJ, Lamendella R, Vázquez-Baeza Y, Walters WA,
Bramer LM, et al. Dynamics of the human gut microbiome in inflammatory
bowel disease. Nat Microbiol. (2017) 2:17004. doi: 10.1038/nmicrobiol.2017.4
4. Weiss GA, Hennet T. Mechanisms and consequences of intestinal dysbiosis.
Cell Mol Life Sci. (2017) 74:2959–77. doi: 10.1007/s00018-017-2509-x
5. Schwingshackl L, Hoffmann G. Comparison of effects of long-term low-
fat vs high-fat diets on blood lipid levels in overweight or obese patients:
a systematic review and meta-analysis. J Acad Nutr Diet. (2013) 113:1640–
61. doi: 10.1016/j.jand.2013.07.010
6. Rohr MW, Narasimhulu CA, Rudeski-Rohr TA, Parthasarathy S. Negative
effects of a high-fat diet on intestinal permeability: a review. Adv Nutr. (2020)
11:77–91. doi: 10.1093/advances/nmz061
7. Preiss D, Sattar N. Lipids, lipid modifying agents and cardiovascular
risk: a review of the evidence. Clin Endocrinol. (2009) 70:815–
28. doi: 10.1111/j.1365-2265.2008.03490.x
8. Velagapudi VR, Hezaveh R, Reigstad CS, Gopalacharyulu P, Yetukuri L, Islam
S, et al. The gut microbiota modulates host energy and lipid metabolism in
mice. J Lipid Res. (2010) 51:1101–12. doi: 10.1194/jlr.M002774
9. Kishino S, Takeuchi M, Park, S.-B., Hirata A, Kitamura N, et al.
Polyunsaturated fatty acid saturation by gut lactic acid bacteria
affecting host lipid composition. Proc Natl Acad Sci. (2013)
110:17808–13. doi: 10.1073/pnas.1312937110
10. Ghazalpour A, Cespedes I, Bennett BJ, Allayee H. Expanding role of
gut microbiota in lipid metabolism. Curr Opin Lipidol. (2016) 27:141–
7. doi: 10.1097/MOL.0000000000000278
11. Wang Z, Koonen D, Hofker M, Fu J. Gut microbiome and lipid
metabolism: from associations to mechanisms. Curr Opin Lipidol. (2016)
27. doi: 10.1097/MOL.0000000000000308
12. Matey-Hernandez ML, Williams FMK, Potter T, Valdes AM,
Spector TD, Menni C. Genetic and microbiome influence on
lipid metabolism and dyslipidemia. Physiol Genomics. (2018)
50:117–26. doi: 10.1152/physiolgenomics.00053.2017
13. Huang X, Fang S, Yang H, Gao J, HeM, Ke S, et al. Evaluating the contribution
of gut microbiome to the variance of porcine serum glucose and lipid
concentration. Sci Rep. (2017) 7:14928. doi: 10.1038/s41598-017-15044-x
14. Fu J, Bonder MJ, Cenit MC, Tigchelaar EF, Maatman A, Dekens
JAM, et al. The gut microbiome contributes to a substantial
proportion of the variation in blood lipids. Circ Res. (2015)
117:817–24. doi: 10.1161/CIRCRESAHA.115.306807
15. Lang JM, Pan C, Cantor RM, Tang WHW, Garcia-Garcia JC, Kurtz I, et al.
Impact of individual traits, saturated fat, and protein source on the gut
microbiome.MBio. (2018) 9:e01604–18. doi: 10.1128/mBio.01604-18
16. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness
of human gut microbiome correlates with metabolic markers. Nature. (2013)
500:541–6. doi: 10.1038/nature12506
17. Le Roy T, Lécuyer E, Chassaing B, Rhimi M, Lhomme M, Boudebbouze S,
et al. The intestinal microbiota regulates host cholesterol homeostasis. BMC
Biol. (2019) 17:94. doi: 10.1186/s12915-019-0715-8
18. Dreon DM, Fernstrom HA, Campos H, Blanche P, Williams PT, Krauss RM.
Change in dietary saturated fat intake is correlated with change in mass
of large low-density-lipoprotein particles in men. Am J Clin Nutr. (1998)
67:828–36. doi: 10.1093/ajcn/67.5.828
19. Sonnenburg ED, Sonnenburg JL. Starving our microbial self: the deleterious
consequences of a diet deficient in microbiota-accessible carbohydrates. Cell
Metab. (2014) 20:779–86. doi: 10.1016/j.cmet.2014.07.003
20. Sonnenburg ED, Smits SA, Tikhonov M, Higginbottom SK, Wingreen NS,
Sonnenburg JL. Diet-induced extinctions in the gut microbiota compound
over generations. Nature. (2016) 529:212–5. doi: 10.1038/nature16504
21. Lam YY, Ha CWY, Hoffmann JMA, Oscarsson J, Dinudom A, Mather TJ,
et al. Effects of dietary fat profile on gut permeability and microbiota and
their relationships with metabolic changes in mice. Obesity. (2015) 23:1429–
39. doi: 10.1002/oby.21122
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